FDA OTAT Launches Gene Therapy CMC Town Hall Series

Gene therapy manufacturers scaling toward BLA submission now have a direct regulatory reference point: FDA's Office of Tissues and Advanced Therapies (OTAT) has launched a virtual town hall series specifically addressing chemistry, manufacturing, and controls expectations for advanced therapy products. The inaugural session, held September 29, 2022, drew on subject matter experts from OTAT's Division of Cell and Gene Therapy to field CMC questions from product development stakeholders.

For plant heads and QA directors operating in the gene therapy space, the session's framing is instructive. FDA's position is that CMC submissions must demonstrate a sponsor's commitment to manufacturing and testing controls that assure product safety, identity, quality, purity, and potency across investigational new drug, biologics license, and new drug applications. That scope covers the full development arc, from early IND-stage process characterisation through to commercial-scale process validation.

The town hall format is Q&A-driven, with OTAT experts responding to pre-submitted stakeholder questions. FDA noted that questions specific to individual investigational products or active drug applications fall outside the scope of the series, a boundary that keeps the dialogue at the level of policy and general CMC principles rather than product-specific guidance. Regulatory affairs leads should treat the published transcript as a primary reference document: the 370.92 KB PDF transcript from the September session is available via the FDA CBER event page and captures the full exchange on record.

The series is positioned as an ongoing engagement mechanism. OTAT has indicated additional town halls will address other regulated product categories, with future sessions listed on the CBER events calendar. For QA teams building out their regulatory intelligence function, the CBER listserv provides advance notice of upcoming sessions, allowing teams to submit questions ahead of each event and shape the published record.

Manufacturers at the IND stage, particularly those developing viral vector-based therapies where potency assay development and comparability protocols remain active regulatory discussion points, will find the transcript a useful benchmark against current OTAT expectations before their next pre-BLA meeting.

Source: FDA CBER / OTAT via FDA.gov (What's New: Vaccines, Blood & Biologics RSS Feed), September 29, 2022. Event transcript (PDF, 370.92 KB) available on the FDA CBER events page.